FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979713530> ?p ?o ?g. }

• W1979713530 endingPage "1250" @default.
• W1979713530 startingPage "1249" @default.
• W1979713530 abstract "Nonreceptor tyrosine kinase Src is found to be overexpressed in many cancers and plays an important role in cancer formation, progression and metastasis via the activation of several downstream signal pathways and cytoskeleton.1-3 Overexpression of Src negative regulator csk suppresses tumor metastasis in a mouse colon cancer model.4 Thus, inhibition of Src could be used for the treatment of those cancers with overexpressed Src. Many small molecules have been developed for the purpose, and several agents are currently under clinical trials.1 Dasatinib is a second-generation Src inhibitor with stronger effect on cancer cells.5 Except Src, Dasatinib also inhibits other kinases or nonkinase proteins. However, its actual effect in cancer treatment still needs further investigation. The article “activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model” by Vitali et al. published in your journal is highly interesting. The study provides an important observation that Dasatinib strongly inhibits the growth of neuroblastoma cells and induces senescence and apoptosis in vitro. However, Dasatinib does not produce the expected effect in vivo. This important issue has to be further understood to improve clinical implication of Dasatinib. I think that this phenomenon may be explained by the inhibition of the immune system in vivo by Dasatinib via Src. Although overexpression of Src plays an important role in the pathogenesis of cancer, the normal expression of Src is necessary for the immune responses.6, 7 Immune responses are critical for surveillance and eradication of cancer cells. In the cancer treatment, weaken cancer cells need to be cleaned by immune cells. Thus, immunotherapy has been used to increase the effect of chemotherapy and reduce the dose of cytotoxicity drugs and therefore reduce their side effects.8 Many studies have demonstrated that inhibition of Src affects both innate and adaptive immune responses. Src has been demonstrated to be important in the activation of macrophage, dendritic cells and natural killer cells.7, 9 It has also been shown to control cytokine production such as production of TNF-alpha stimulated by LPS, which is inhibited by Dasatinib.10 Through DC and cytokine production, it can affect adaptive immunity. Evidence has shown the important role of Src in T-cell development.11 Indeed, Dasatinib has been shown to inhibit effector CD4+, CD8+ T-cells,12, 13 NK cells9 and CD4+ CD25+ regulatory T cells.14 A recent study has investigated Dasatinib for its immunosuppression effect in 16 CML patients at a dose of 140 mg/day.15 In these patients, Dasatinib has caused decreases in cell numbers of T-cells, B-cells and natural killer cells. The decreased immune responses caused by Dasatinib may be associated with observed increased infections and formation of skin cancer in Dasatinib-treated patients.15 It will be interesting to further examine the immune system in the model used by Vitali et al. The insight into immune responses altered by Dasatinib may have implications in the design of therapy regime either by adding immune therapy agents or reducing the dosage but used with other chemotherapy drugs so that the immune system is well maintained when aiming to weaken cancer cells by the inhibition of the Src signal pathway. Indeed, the combination therapy with cytotoxic agent has been used to achieve good outcome. The combination with immunotherapy may also produce better outcome. Yours sincerely, Jiezhong Chen." @default.
• W1979713530 created "2016-06-24" @default.
• W1979713530 creator A5058107287 @default.
• W1979713530 date "2009-12-17" @default.
• W1979713530 modified "2023-10-16" @default.
• W1979713530 title "Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo" @default.
• W1979713530 cites W1484255426 @default.
• W1979713530 cites W1968685079 @default.
• W1979713530 cites W1994309500 @default.
• W1979713530 cites W2002185737 @default.
• W1979713530 cites W2002563149 @default.
• W1979713530 cites W2025757800 @default.
• W1979713530 cites W2036118441 @default.
• W1979713530 cites W2036988959 @default.
• W1979713530 cites W2047046033 @default.
• W1979713530 cites W2058404952 @default.
• W1979713530 cites W2082620735 @default.
• W1979713530 cites W2152024997 @default.
• W1979713530 cites W2156222101 @default.
• W1979713530 doi "https://doi.org/10.1002/ijc.25121" @default.
• W1979713530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20020494" @default.
• W1979713530 hasPublicationYear "2009" @default.
• W1979713530 type Work @default.
• W1979713530 sameAs 1979713530 @default.
• W1979713530 citedByCount "2" @default.
• W1979713530 countsByYear W19797135302015 @default.
• W1979713530 countsByYear W19797135302021 @default.
• W1979713530 crossrefType "journal-article" @default.
• W1979713530 hasAuthorship W1979713530A5058107287 @default.
• W1979713530 hasBestOaLocation W19797135301 @default.
• W1979713530 hasConcept C108636557 @default.
• W1979713530 hasConcept C121608353 @default.
• W1979713530 hasConcept C126322002 @default.
• W1979713530 hasConcept C150903083 @default.
• W1979713530 hasConcept C184235292 @default.
• W1979713530 hasConcept C203014093 @default.
• W1979713530 hasConcept C207001950 @default.
• W1979713530 hasConcept C2776715637 @default.
• W1979713530 hasConcept C2778820342 @default.
• W1979713530 hasConcept C2779013556 @default.
• W1979713530 hasConcept C2779536868 @default.
• W1979713530 hasConcept C2779976819 @default.
• W1979713530 hasConcept C42362537 @default.
• W1979713530 hasConcept C502942594 @default.
• W1979713530 hasConcept C54355233 @default.
• W1979713530 hasConcept C62478195 @default.
• W1979713530 hasConcept C71924100 @default.
• W1979713530 hasConcept C81885089 @default.
• W1979713530 hasConcept C86803240 @default.
• W1979713530 hasConcept C8891405 @default.
• W1979713530 hasConcept C95444343 @default.
• W1979713530 hasConcept C96232424 @default.
• W1979713530 hasConceptScore W1979713530C108636557 @default.
• W1979713530 hasConceptScore W1979713530C121608353 @default.
• W1979713530 hasConceptScore W1979713530C126322002 @default.
• W1979713530 hasConceptScore W1979713530C150903083 @default.
• W1979713530 hasConceptScore W1979713530C184235292 @default.
• W1979713530 hasConceptScore W1979713530C203014093 @default.
• W1979713530 hasConceptScore W1979713530C207001950 @default.
• W1979713530 hasConceptScore W1979713530C2776715637 @default.
• W1979713530 hasConceptScore W1979713530C2778820342 @default.
• W1979713530 hasConceptScore W1979713530C2779013556 @default.
• W1979713530 hasConceptScore W1979713530C2779536868 @default.
• W1979713530 hasConceptScore W1979713530C2779976819 @default.
• W1979713530 hasConceptScore W1979713530C42362537 @default.
• W1979713530 hasConceptScore W1979713530C502942594 @default.
• W1979713530 hasConceptScore W1979713530C54355233 @default.
• W1979713530 hasConceptScore W1979713530C62478195 @default.
• W1979713530 hasConceptScore W1979713530C71924100 @default.
• W1979713530 hasConceptScore W1979713530C81885089 @default.
• W1979713530 hasConceptScore W1979713530C86803240 @default.
• W1979713530 hasConceptScore W1979713530C8891405 @default.
• W1979713530 hasConceptScore W1979713530C95444343 @default.
• W1979713530 hasConceptScore W1979713530C96232424 @default.
• W1979713530 hasIssue "5" @default.
• W1979713530 hasLocation W19797135301 @default.
• W1979713530 hasLocation W19797135302 @default.
• W1979713530 hasOpenAccess W1979713530 @default.
• W1979713530 hasPrimaryLocation W19797135301 @default.
• W1979713530 hasRelatedWork W1543323431 @default.
• W1979713530 hasRelatedWork W1560827802 @default.
• W1979713530 hasRelatedWork W2042132765 @default.
• W1979713530 hasRelatedWork W2081039253 @default.
• W1979713530 hasRelatedWork W2516360709 @default.
• W1979713530 hasRelatedWork W2528645419 @default.
• W1979713530 hasRelatedWork W2556047608 @default.
• W1979713530 hasRelatedWork W2737510744 @default.
• W1979713530 hasRelatedWork W2737698771 @default.
• W1979713530 hasRelatedWork W2803282923 @default.
• W1979713530 hasVolume "127" @default.
• W1979713530 isParatext "false" @default.
• W1979713530 isRetracted "false" @default.
• W1979713530 magId "1979713530" @default.
• W1979713530 workType "article" @default.